First Amendment to Employment Agreement between MYMD Pharmaceuticals, Inc. and Paul M. Rivard, Esq.

Contract Categories: Human Resources › Employment Agreements
Summary

MYMD Pharmaceuticals, Inc. and Paul M. Rivard, Esq. have amended their original employment agreement dated September 21, 2020. The amendment updates Exhibit C, which now specifies that Mr. Rivard will receive a $20,000 bonus each time a listed patent application is issued to the company. Each bonus is payable within 30 days after the company receives the issued patent. The amendment details the relevant patent applications and their estimated issuance dates.

Read More Arrow
EX-10.18 13 ex10-18.htm

 

Exhibit 10.18

 

First Amendment to Employment Agreement

 

WHEREAS, MYMD Pharmaceuticals. Inc (the “Company”) and Paul M. Rivard, Esq. (“Employee”) (collectively “the Parties”) entered into an Employment Agreement dated September 21, 2020 (“Agreement”); and

 

WHEREAS, for good and valuable consideration the Parties hereby wish to amend the Agreement as follows:

 

Exhibit “C” to the Agreement is replaced with the Exhibit “C” appended hereto.

 

  MYMD Pharmaceuticals, Inc.
   
  /s/ James A. McNulty
  By: James A. McNulty, CEO
   
  Paul M. Rivard, Esq.
   
  /s/ Paul M. Rivard, Esq.

 

1

 

 

EXHIBIT “C”

 

Milestone Bonuses due upon achievement of milestones

 

Set forth below is the schedule pursuant to which the Employee will be paid $20,000 at the time each of the pending patent applications are issued to the Company. Each bonus will be paid 30 days after receipt of the Issued Patent.

 

Title   Assignee   App. No.   Estimated (Actual) Issuance
Methods of Reversing Normal Aging Process and Extending Lifespan   MyMD Pharmaceuticals, Inc.   16/680,677   2Q 2021
             
Pharmaceutical Salts of Isomyosmine and Pharmaceutical Compositions Containing Same   MyMD Pharmaceuticals, Inc.   16/672,714   (10/20/2020)
             
Method of Regulating Tumor Necrosis Factor-alpha (TNF-α) for Treating Cancers, Autoimmune Disorders, and Other Disorders Associated with Chronic Inflammation   MyMD Pharmaceuticals, Inc.   16/785,747   (11/17/2020)
             
Method of Treating Viral Infections   MyMD Pharmaceuticals, Inc.   16/791,290   (9/29/2020)
             
Method of Treating Coronavirus   MyMD Pharmaceuticals, Inc.   16/792,492   1Q 2021
             
Methods of Regulating Oxidoreductase for Treatment of Aging and Age-related Disorders   MyMD Pharmaceuticals, Inc.   16/928,255   4Q 2021
             
Method of Treating Disorders Associated with Chronic Inflammation   MyMD Pharmaceuticals, Inc.   17/084,012   1Q 2022
             
Synthetic Cannabinoid Compounds for Treatment of Substance Addiction and Other Disorders   Supera Pharmaceuticals, Inc.   16/612,472   1Q 2021

 

2